News

The study is designed to evaluate the safety and preliminary efficacy of PV-10 in five subjects with recurrent breast carcinoma. PV-10 will be injected into one or more

The approval was based on the intergroup exemestane study (IES) which showed that patients who switched to Aromasin after 2-3 years of tamoxifen, for a combined total of

Under the terms of the contract, DVC will develop and optimize preclinical testing models, assess immune response and develop new tularemia vaccine candidates. The company will collaborate on

The new indication includes the treatment of moderate to severe plaque psoriasis in adults who have failed to respond to other systemic therapy. The European Commission approval results

The data show that TroVax is safe and well-tolerated in the renal cell carcinoma patient group and that it induces a strong anti-tumour immune response against the 5T4

Using its antibody technology, Abmaxis will further optimize and humanize antibodies developed by BioArctic. Under the terms of the agreement, BioArctic will pay Abmaxis an upfront technology license

Although the secretin drug, RG1068, proved ineffective in treating positive symptoms of the disease during a previous phase II trial, several patients showed cognitive improvements following drug administration.

KC706 is a novel anti-inflammatory drug that works by inhibiting the activity of p38 MAP kinase. Kemia predicts the drug may be useful for treating inflammatory conditions such

Schering AG will market the product in Europe, and in other countries where Vasovist may receive approval. Millions of people worldwide suffer from various forms of vascular disease.